Quest Partners LLC Sells 4,177 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Quest Partners LLC reduced its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 86.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 632 shares of the company’s stock after selling 4,177 shares during the period. Quest Partners LLC’s holdings in Keros Therapeutics were worth $37,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KROS. KBC Group NV boosted its position in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter worth $216,000. AlphaCentric Advisors LLC bought a new stake in shares of Keros Therapeutics during the 3rd quarter valued at about $465,000. Emerald Advisers LLC bought a new position in Keros Therapeutics in the third quarter worth approximately $9,032,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Keros Therapeutics in the third quarter worth about $6,539,000. 71.56% of the stock is owned by institutional investors.

Analysts Set New Price Targets

KROS has been the subject of a number of recent analyst reports. Bank of America dropped their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Guggenheim began coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective on the stock. Finally, Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective for the company. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $57.74 on Monday. The company has a market cap of $2.34 billion, a PE ratio of -11.08 and a beta of 1.23. Keros Therapeutics, Inc. has a 52-week low of $27.31 and a 52-week high of $73.00. The firm’s 50 day moving average price is $59.49 and its 200-day moving average price is $52.28.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.33) EPS. On average, analysts forecast that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.